Hong Kong Stocks Update | INSILICO Surges Over 9% as ISM8969/HT-001 Receives NMPA Clinical Trial Approval for Parkinson's Disease Treatment

Stock News08-07 14:10

Insilico Medicine (03696) surged more than 9%, trading up 8.1% at HK$44.3 as of the latest update, with a turnover of HK$541 million.

According to recent news from Insilico's official WeChat account, the company announced that the innovative oral NLRP3 inhibitor ISM8969/HT-001, co-developed with Hengtai Biotech, has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of Parkinson's disease.

Following the completion of the first participant dosing in a Phase I clinical trial in Australia in June 2026, this approval marks the official start of parallel clinical evaluations in both China and Australia. The study aims to assess the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of ISM8969/HT-001 in healthy participants, as well as its preliminary efficacy in Parkinson's disease patients, laying the groundwork for further clinical development.

Previously, in January 2026, Insilico Medicine announced an exclusive licensing and collaboration agreement with Shenzhen Pengfu Fund, under Fosun Health Capital, and Hygtia Therapeutics, a portfolio company of Fosun Pharma, to jointly advance the global development of ISM8969/HT-001. Under the terms, both parties hold a 50% global stake in the project, with Insilico entitled to receive over HK$500 million in upfront and milestone payments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment